Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age

Indian Journal of Medical Research

Volumn 118, Issue NOV., 2003, Pages 183-186

  Yadav, Sangita ^a   Thukral, Richa ^a   Chakarvarti, Anita ^a  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

Measles; MMR vaccine; Mumps; Rubella vaccine

Indexed keywords

IMMUNOGLOBULIN G; MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; MUMPS ANTIBODY; RUBELLA ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; GEOMETRY; HOSPITAL; HUMAN; IMMUNIZATION; INDIA; INFANT; MEASLES; MUMPS; OUTPATIENT DEPARTMENT; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RUBELLA; SEROCONVERSION; SERODIAGNOSIS; SEROLOGY; SINGLE DRUG DOSE; VACCINATION;

AGE FACTORS; COHORT STUDIES; HUMANS; INDIA; INFANT; MEASLES-MUMPS-RUBELLA VACCINE;

EID: 0347917310     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bhargava I. Control of Measles, Mumps and Rubella. New Delhi: B.I. Churchill Livingstone Pvt. Ltd.; 1995 p. 41, 105,154-5.
2. Measles control-South East Asia region (1990-1997). MMWR 1999; 48 : 541-5.
3. Krugman S. Mumps (epidemic parotitis) In: Krugman S. editor. Krugman's Infectious Diseases of Children. St Louis, Missouri: The CV Mosby Co; 1992; 9 : 373-6.
4. Seth P, Manjunath N, Balaya S. Rubella infection, the Indian scene. Rev Infect Dis 1985; 7 (Suppl 1) : S64-7.
5. Chakrabarty MS, Das BC, Gupta B, Sarkar JK. Rubella as an aetiological factor of congenital malformation in Calcutta - A serological study. Indian J Med Res 1975; 63 : 1438-45.
6. Chaturvedi UC, Tripathi BN, Mathur A, Singh UK, Mehrotra RML. Role of rubella in congenital malformations in India. J Hyg (Lond.) 1976; 76 : 33-40.
7. Bhaskaram P, Ramalakshmi BA, Raju LA, Raman L. Need for protection against rubella in India. Indian J Pediatr 1991; 58 : 811-4.
8. Schoub BD, Johnson S, McAnerney JM, Wagstaff LA, Matsie W, Reinach SG, et al. Measles, mumps and rubella immunization at nine months in a developing country. Pediatr Infect Dis J 1990; 9 : 263-7.
9. Singh R, John TJ, Cherian T, Raghupathy P. Immune response to measles, mumps and rubella vaccine at 9, 12 and 15 months of age. Indian J Med Res 1994; 100 : 155-9.
10. Bhargava I, Chhaparwal BC, Phadke MA, Irani SF, Chhaparwal D, Dhorje S, et al. Immunogenicity and reactogenicity of indigenously produced MMR vaccine. Indian Pediatr 1995; 323 : 983-8.
11. Chakravarti A, Yadav S, Berry N, Rastogi A, Mathur MD. Evaluation of serological status of rubella and mumps in children below five years. Indian J Med Res 1999; 110 : 1-3.
12. Giammanco G, Li Volti S, Salemi I, Giammanco Bilancia G, Mauro L. Immune response to simultaneous administration of a combined measles, mumps and rubella vaccine with booster doses of diphtheria-tetanus and poliovirus vaccine. Eur J Epidemiol 1993; 9 : 199-202.
13. Edees S, Pullan CR, Hull D. A randomized single blind trial of a combined mumps measles, rubella vaccine to evaluate serological response and reactions in the UK population. Public Health 1991; 105 : 91-7.
14. Lerman SJ, Bellinger M, Brunken JM. Clinical and serologic evaluation of measles, mumps and rubella (HPV-77 : DE-5 and RA 27/3) virus vaccines singly and in combination. Pediatrics 1981; 68 : 18-22.
15. Paniker AR, Jayaram CK. Immune response. In : Textbook of Microbiology. Hyderabad : Orient Longman, 1990 p. 127-46.
16. Immunization Advisory Committee Report and Recommendations. Bombay: Indian Academy of Pediatrics (IAP), 1994.
17. White CC, Koplan JP, Orenstein WA. Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health 1985; 75 : 739-44.
18. Koplan JP, Preblud SR. A benefit-cost analysis of mumps vaccine. Am J Dis Child 1982; 136 : 362-4.
19. Mittal S, Rastogi A, Yadav S. Should MMR be included in EPI? Paediatr Today 1999; 2 : 32-5.